Table 2 Psoriasis severity and plasma PUFA concentrations (mol %) by sex
Characteristic | Total (n = 296) | Male (n = 228) | Female (n = 68) | p-value |
|---|---|---|---|---|
ClinROs | ||||
 PASI | 11.5 (8.5, 15.5) | 12.0 (9.3, 16.8) | 9.8 (7.5, 12.0) | 0.001 |
 BSA | 13.0 (9.5, 21.5) | 13.6 (10.0, 24.0) | 10.9 (7.5, 14.8) | < 0.0001 |
 PGA | 3.0 (2.7, 3.3) | 3.9 (2.7, 3.5) | 2.7 (2.3, 3.0) | 0.001 |
PROs | ||||
 PtGA | 7.0 (5.0, 8.0) | 7.0 (5.0, 8.0) | 7.0 (5.0, 9.0) | 0.708 |
 DLQI | 8.0 (4.0, 14.0) | 8.0 (4.0, 14.0) | 9.0 (5.0, 14.0) | 0.676 |
Plasma PUFAs (mol %) | ||||
 Omega-3 | ||||
  α-Linolenic acid (18:3n3) | 1.95 (1.44, 2.90) | 1.99 (1.44, 2.99) | 1.84 (1.34, 2.38) | 0.206 |
  Eicosapentaenoic acid (20:5n3) | 0.69 (0.51, 1.00) | 0.67 (0.50, 0.99) | 0.71 (0.56, 1.05) | 0.352 |
  Docosahexaenoic acid (22:6n3) | 4.42 (3.69, 5.36) | 4.34 (3.53, 5.30) | 4.62 (4.13, 5.72) | 0.008 |
  Omega-3 PUFAs | 7.44 (6.36, 8.74) | 7.34 (6.28, 8.67) | 7.76 (6.47, 8.93) | 0.159 |
 Omega-6 | ||||
  Linoleic acid (18:2n6-cis) | 23.74 (21.98, 25.54) | 23.74 (22.04, 25.56) | 23.69 (21.60, 25.19) | 0.343 |
  Eicosadienoic acid (20:2n6) | 0.71 (0.62, 0.79) | 0.71 (0.62, 0.80) | 0.70 (0.62, 0.76) | 0.167 |
  Dohomo-γ-linolenic acid (20:3n6) | 0.06 (0.05, 0.08) | 0.06 (0.05, 0.08) | 0.06 (0.05, 0.08) | 0.520 |
  Arachidonic acid (20:4n6) | 13.17 (11.03, 15.44) | 12.86 (10.65, 15.20) | 13.61 (11.91, 16.17) | 0.032 |
  Omega-6 PUFAs | 38.21 (35.39, 40.80) | 37.96 (35.34, 40.80) | 38.70 (35.94, 40.95) | 0.379 |
  Omega-6/3 ratio | 5.01 (4.28, 6.17) | 5.08 (4.28, 6.25) | 4.89 (4.27, 6.09) | 0.313 |